Subtopic Deep Dive
EGFR Mutations Lung Cancer
Research Guide
What is EGFR Mutations Lung Cancer?
EGFR Mutations Lung Cancer refers to activating mutations in the epidermal growth factor receptor gene driving non-small cell lung cancer, targeted by tyrosine kinase inhibitors like gefitinib with initial responses limited by resistance mutations such as T790M.
Activating EGFR mutations occur in 10-15% of non-small cell lung cancers, particularly in never-smokers and Asians, leading to sensitivity to TKIs. Resistance emerges via secondary mutations like T790M, detected in over 50% of cases post-TKI failure. Over 200 papers document mechanisms and therapies, with foundational work by Yun et al. (2008, 2062 citations) and Gazdar (2009, 966 citations).
Why It Matters
EGFR TKIs like gefitinib extend progression-free survival from months to over a year in mutation-positive NSCLC patients, transforming treatment from chemotherapy to precision oncology (Gazdar, 2009). T790M resistance mechanisms identified by Yun et al. (2008) enabled third-generation inhibitors like osimertinib, improving outcomes in 60-70% of resistant cases. Next-generation sequencing of EGFR pathways guides clinical trials and companion diagnostics, reducing ineffective treatments and healthcare costs in lung cancer management.
Key Research Challenges
T790M Resistance Mechanism
T790M mutation increases EGFR kinase ATP affinity, reducing TKI binding and causing acquired resistance after initial response (Yun et al., 2008). This affects over 50% of gefitinib-resistant NSCLC cases. Developing mutant-selective inhibitors remains critical (Jia et al., 2016).
C797S Double Resistance
C797S mutation emerges after TKI therapy, conferring resistance to third-generation inhibitors in T790M-positive tumors (Jia et al., 2016). Allosteric inhibitors targeting both mutations show promise but face clinical translation hurdles. Sequencing-based detection lags behind resistance evolution.
Heterogeneous Resistance Pathways
Beyond EGFR mutations, MET amplification and histologic transformation drive 20-30% of resistance cases (Jackman et al., 2009). Single-biopsy sampling misses polyclonal resistance. Liquid biopsy NGS improves detection but requires validation in diverse populations.
Essential Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · 2008 · Proceedings of the National Academy of Sciences · 2.1K citations
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these ag...
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. · 2020 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the t...
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han et al. · 2022 · Signal Transduction and Targeted Therapy · 1.3K citations
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross, Elzbieta Slodkowska, W. Fraser Symmans et al. · 2009 · The Oncologist · 1.1K citations
Learning Objectives Contrast the current strengths and limitations of the three main slide-based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer tissues for HER...
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du, Christine M. Lovly · 2018 · Molecular Cancer · 1.0K citations
Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK signaling leads...
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne · 2021 · Nature Reviews Drug Discovery · 980 citations
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Adi F. Gazdar · 2009 · Oncogene · 966 citations
Reading Guide
Foundational Papers
Start with Yun et al. (2008) for T790M mechanism (2062 citations), then Gazdar (2009) for mutation-response links (966 citations), and Jackman et al. (2009) for resistance definitions (776 citations) to build core understanding of TKI dynamics.
Recent Advances
Study Jia et al. (2016) for C797S allosteric inhibitors (843 citations) and Li et al. (2021) for HER2-mutant NSCLC parallels (870 citations) to grasp next-generation targeting advances.
Core Methods
Core techniques include NGS for mutation detection, co-crystal structures for TKI binding (Yun et al., 2008), PFS analysis from phase III trials (Jackman et al., 2009), and allosteric inhibitor design (Jia et al., 2016).
How PapersFlow Helps You Research EGFR Mutations Lung Cancer
Discover & Search
Research Agent uses searchPapers('EGFR T790M lung cancer resistance') to retrieve Yun et al. (2008) with 2062 citations, then citationGraph reveals 500+ citing papers on osimertinib, while findSimilarPapers expands to Jia et al. (2016) for C797S inhibitors.
Analyze & Verify
Analysis Agent applies readPaperContent on Yun et al. (2008) to extract ATP affinity kinetics data, verifyResponse with CoVe cross-checks mutation prevalence against Gazdar (2009), and runPythonAnalysis plots survival curves from Jackman et al. (2009) PFS data using pandas, graded A by GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in T790M allosteric targeting post-Jia et al. (2016), flags contradictions between IHC/FISH methods in Ross et al. (2009), while Writing Agent uses latexEditText for mutation pathway revisions, latexSyncCitations for 20 EGFR papers, and latexCompile generates a review manuscript with exportMermaid for resistance cascade diagrams.
Use Cases
"Extract survival data from EGFR TKI resistance papers and plot PFS curves"
Research Agent → searchPapers('EGFR TKI PFS NSCLC') → Analysis Agent → readPaperContent(Jackman 2009) → runPythonAnalysis(pandas/matplotlib plot median PFS 9.7 vs 13.1 months) → researcher gets publication-ready survival figure.
"Write LaTeX section on T790M mechanisms with citations"
Synthesis Agent → gap detection(Yun 2008) → Writing Agent → latexEditText('T790M increases ATP affinity') → latexSyncCitations(10 papers) → latexCompile → researcher gets formatted subsection with inline citations and compiled PDF.
"Find code for EGFR mutation NGS analysis from papers"
Research Agent → searchPapers('EGFR NGS lung cancer code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(alignment scripts) → researcher gets runnable NGS variant calling pipeline linked to Gazdar 2009 methods.
Automated Workflows
Deep Research workflow scans 50+ EGFR lung cancer papers via searchPapers → citationGraph → structured report ranking T790M therapies by citations. DeepScan's 7-step chain verifies Yun et al. (2008) claims with CoVe against 20 citing papers, checkpointing mutation kinetics. Theorizer generates hypotheses on C797S allosteric inhibitors from Jia et al. (2016) + Du & Lovly (2018) RTK mechanisms.
Frequently Asked Questions
What defines EGFR mutations in lung cancer?
Activating mutations in EGFR exons 19-21 drive 10-15% of NSCLC, causing constitutive kinase activity responsive to TKIs like gefitinib (Gazdar, 2009).
What are main methods for EGFR resistance detection?
Repeat biopsy or liquid biopsy NGS detects T790M in 50-60% of resistant cases; IHC/FISH validate mutation status (Yun et al., 2008; Jackman et al., 2009).
What are key papers on EGFR TKI resistance?
Yun et al. (2008, 2062 citations) defines T790M ATP affinity mechanism; Gazdar (2009, 966 citations) links mutations to TKI response; Jia et al. (2016, 843 citations) addresses C797S.
What open problems exist in EGFR lung cancer research?
Overcoming polyclonal resistance beyond T790M/C797S, like MET bypass; validating allosteric inhibitors clinically; improving NGS for early mutation detection pre-resistance.
Research HER2/EGFR in Cancer Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching EGFR Mutations Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the HER2/EGFR in Cancer Research Research Guide